The Nightingale Continuum
People with ME/ICC often describe a progressive loss of functional capacity that can feel like “fading away,” as the illness steadily reduces energy availability, cognitive endurance, and physical tolerance. This is not simple fatigue, but a systemic impairment of energy production and recovery, where even minimal exertion can lead to disproportionate and prolonged deterioration rather than normal recovery. Over time, patients may be forced into an ever-narrowing envelope of tolerable activity, with a marked reduction in baseline function and increasing loss of independence.
Despite growing biomedical evidence, ME/ICC remains widely under-recognised in clinical practice. Many clinicians receive limited training in the condition, and its complex, multi-system nature combined with the lack of consistent routine biomarkers can contribute to misinterpretation of symptoms and underestimation of severity. As a result, patients are frequently dismissed or not fully believed, not necessarily due to intent, but due to persistent gaps in clinical understanding and outdated assumptions about the illness.
Closing the gap in ME/ICC care requires action at several levels; clinical education, diagnostics, healthcare systems, and patient protection. The key is shifting from misunderstanding and variability in practice toward consistency, validation, and biomedical literacy.
At the clinical level, a major step is improving medical education. ME/ICC needs to be properly integrated into undergraduate medical training, postgraduate programs, and continuing professional development. This includes teaching the ICC/updated biomedical models, post-exertional Neuroimmune exhaustion, autonomic and immune involvement, and the harms of inappropriate “graded exercise” approaches. Clinicians don’t just need awareness, they need practical competence in recognition and safe management.
Diagnosis is another critical gap. Earlier and more consistent use of validated diagnostic criteria, combined with structured clinical assessment tools, would reduce misdiagnosis and delay. Clinicians also need guidance on excluding common mimics while recognising that standard investigations can appear normal despite significant disability.
On the system side, care pathways should be formalised so patients are not left navigating fragmented services. Multidisciplinary models that include neurology, immunology, cardiology (for orthostatic intolerance), and rehabilitation medicine, grounded in energy-limiting principles, can reduce harm and improve continuity of care. Access to disability supports should also be based on functional impairment rather than fluctuating day-to-day presentation.
Equally important is shifting the clinical culture: validating patient-reported symptoms as clinically meaningful data, not subjective noise. ME/ICC is one of the conditions where patient history is central to diagnosis, and failing to treat it as such perpetuates under-recognition.
Finally, research investment needs to focus on proper stratification, objective biomarkers, metabolic dysfunction, neuroimmune dysregulation, and post-exertional pathophysiology. Without measurable biological targets, clinical uncertainty will continue to feed inconsistency in care.
In short, closing the gap means better education, clearer diagnostic practice, safer care pathways, and a stronger commitment to biomedical research paired with a cultural shift toward taking patient experience seriously as evidence, not opinion.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12346739/….
https://pmc.ncbi.nlm.nih.gov/articles/PMC3973969/….
https://www.sciencedirect.com/…/abs/pii/S0002934325000932
https://www.healthlinkbc.ca/…/myalgic…
